Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTP4A3 | O75365 | 7/20 | 0.72 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | NAT1 | P18440 | 3/20 | 0.55 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065370 | 1.00 | PTP4A3 (0.72) | PTP4A3GSK3BNAT1CISD1PTPN1 | |
| SCHEMBL2065369 | 1.00 | PTP4A3 (0.72) | PTP4A3GSK3BNAT1CISD1PTPN1 | |
| SCHEMBL5317220 | 0.96 | PTP4A3 (0.67) | PTP4A3GSK3BNAT1CISD1PTPN1 | |
| SCHEMBL5317218 | 0.96 | PTP4A3 (0.67) | PTP4A3GSK3BNAT1CISD1PTPN1 | |
| SCHEMBL2065177 | 0.92 | PTP4A3 (0.66) | PTP4A3GSK3BNAT1CISD1PTPN1 | |
| SCHEMBL10090256 | 0.92 | PTP4A3 (0.66) | PTP4A3GSK3BNAT1CISD1PTPN1 | |
| SCHEMBL2065174 | 0.92 | PTP4A3 (0.66) | PTP4A3GSK3BNAT1CISD1PTPN1 | |
| SCHEMBL2065636 | 0.91 | PTP4A3 (0.62) | PTP4A3GSK3BNAT1CISD1PDE4B | |
| SCHEMBL2065635 | 0.91 | PTP4A3 (0.62) | PTP4A3GSK3BNAT1CISD1PDE4B | |
| SCHEMBL10090260 | 0.91 | PTP4A3 (0.62) | PTP4A3GSK3BNAT1CISD1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | disclosed |
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
| WO-2007081091-A1 | RHODANDSE DERIVARIVES, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | PTPRR, PTPRG, PTPRS | PTP4A3 28/4885GSK3B 390/4885NAT1 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.